The DF/HCC Program in Biostatistics and Computational Biology fosters a broad range of research into statistical, computational and mathematical questions that arise in cancer investigations. Its members are engaged in trans-disciplinary and inter-programmatic projects across population, clinical and basic cancer research. Biostatistics has been a Program since the formation of DF/HCC and was rated as outstanding at the time ofthe last CCSG renewal. The name ofthe Program was changed to Biostatistics and Computational Biology in 2010, with the support ofthe EAB, in order to recognize the strong contribution of computational biologists. This Program is led by G. Parmigiani and R. Betensky and has 45 members from all member institutions. Members are affiliated with two departments at HSPH (Biostatistics and Epidemiology) and six departments at HMS (Biological Chemistry and Molecular Pharmacology, Population Medicine, Medicine, Health Care Policy, Pediatrics and Radiation Oncology). The Program has two Specific Aims: 1) to develop and disseminate new tools in statistical science and computational biology that respond to emerging areas of cancer research;and 2) to develop software for the implementation of these tools. The Biostatistics and Computational Biology Program continues to be highly successful in securing external funding. In 2009, peer-reviewed grant funding attributed to the Program was $14.4 million in total costs, of which nearly $7 million was from NCI (49%) and $7.4 million was from other peer-reviewed sponsors. Attesting to the productivity and interactivity ofthe Program are the 1,666 publications authored by members during the project period, of which 4.2% were intra-programmatic, 44% were inter-programmatic and 33% were inter-institutional collaborations.

Public Health Relevance

The DF/HCC Program in Biostatistics and Computational Biology fosters research into the mathematical, computational, and statistical questions that arise in cancer research. It supports methodological as well as inter-disciplinary and inter-programmatic research across population, clinical and basic cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601461
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$82,029
Indirect Cost
$60,777
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268
Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 371 publications